

PHARMING REPORTS ON FINANCIAL RESULTS FOR THE FIRST NINE MONTHS OF 2013

Leiden, The Netherlands, 7 November 2013. Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today published its financial report for the first nine months of 2013.

FINANCIAL HIGHLIGHTS

- Revenues and other income increased to €6.0 million (9M 2012: €2.4 million), mainly as a result of a US\$ 5 million (€3.8 million) milestone payment by our US partner Santarus on the receipt of FDA acceptance for review of the BLA for Ruconest;
- Operating costs from continuing operations decreased to €9.3 million (9M 2012: €17.9 million), driven by reductions following the 2012 restructuring and lowering of project costs regarding Ruconest®;
- Financial income and expenses increased to €7.4 million (9M 2012: €5.5 million), primarily as a result of non-cash financial costs relating to the January 2013 €16.35 million convertible bond (2012 costs mainly related to the €8.0 million 2012 convertible bond);
- The net loss decreased to €11.1 million (9M 2012: €24.2 million), including the €7.4 million (9M 2012: €5.5 million) of net financing loss;
- Net cash outflows from operations decreased to €7.1 million (9M 2012: €11.6 million) while net cash inflows from financing activities amounted to €14.2 million (including €16.0 million from the issue of convertible bonds) and net cash inflows from investing activities amounted to €0.2 million received upon transfer of an intangible fixed asset;
- Cash at the end of the third quarter of 2013 amounted to €13.5 million (2012 FY: €6.3 million). The negative equity position decreased to €1.6 million from €7.7 million at year end 2012;
- Post events: On 1 October, the Company re-deeemed the final tranche (€2.35 million) of the January 2013 Convertible Bond in cash. On 9 October the Company announced a €12.0 million private placement with institutional investors. As a result of this private placement, Pharming's equity position has become positive again for the first time since December 2011;
- A reverse share split 10:1 was approved at the EGM of 28 February 2013. The total number of shares as of today, 7 November 2013 is 332,434,319.

OPERATIONAL HIGHLIGHTS

- Biologics License Application (BLA) for RUCONEST® was filed and subsequently accepted by the US Food and Drug Administration (FDA)
 - Pharming and Santarus are seeking U.S. marketing approval of RUCONEST® for the treatment of acute angioedema attacks in patients with hereditary angioedema (HAE);
 - Pharming and Santarus were recently informed by the FDA that an Advisory Committee is not likely to be required as part of the RUCONEST review;
 - Pharming and Santarus expect the FDA will complete its review or otherwise respond to the RUCONEST® BLA by 16 April 2014.
- European Medicines Agency (EMA) provided approval for Sanofi Chimie, Pharming's Contract Manufacturing Organization partner, to manufacture drug substance for Pharming's product RUCONEST® at their Aramon (France) site, completing an important up-scaling of the production capacity that will allow for future significant economies of scale.
- New data from a pivotal Phase III clinical study (Study 1310) of RUCONEST® for the treatment of acute angioedema attacks in patients with hereditary angioedema (HAE) featured in a poster presentation at the European Academy of

Allergy and Clinical Immunology (EAACI) & World Allergy Organization (WAO) World Allergy & Asthma Congress in Milan, Italy.

- Results of a study demonstrating that RUCONEST® has been shown to have a beneficial effect as a donor pre-treatment therapy in an animal model of kidney transplantation was presented at the American Transplant Congress in Seattle, Washington.
- The Company entered into a strategic collaboration in China with Shanghai Institute of Pharmaceutical Industry (SIPI), a Sinopharm Company, for the development, manufacture and commercialisation of new products at SIPI, funded by SIPI upto IND stage, based on the Pharming technology platform. In addition, Pharming has also granted SIPI an exclusive license to commercialise RUCONEST® (conestat alfa) in China.
- For HAE prophylaxis, we submitted, under our investigational new drug application, a protocol to the FDA with a request for a special protocol assessment, or SPA. The FDA has indicated that modifications to the protocol are needed before proceeding with the study and further discussions will be required in order for the protocol to be approved pursuant to the SPA process. We and Santarus are evaluating next steps to move the program forward.

Sijmen De Vries, Chief Executive of Pharming commented: “During the third quarter we have continued to build on the positive momentum experienced in the first six months of 2013; momentum which allowed us to further strengthen our balance sheet through a successful €12.0 million private placement with institutional investors, completed directly after closing of the third quarter. This was an important event for Pharming: as well as strengthening of our balance sheet, the placement demonstrated the continued support of our existing institutional shareholders as well providing new institutional shareholders with the opportunity to take a position in Pharming. Significantly, the private placing occurred after we fully redeemed the January 2013 Convertible Bond. Together with our US partner Santarus, our team continues to work on the ongoing FDA review of RUCONEST® and in this context we are pleased to note today that the FDA has recently informed us that an Advisory Committee is not likely to be required as part of the RUCONEST® review.

FINANCIAL RESULTS

In the nine months to 30 September 2013 the Company generated revenue and other income of €6.0 million (9M 2012: €2.4 million). This increase results from a license fee following achievement of the US\$ 5 million milestone from our US partner Santarus for FDA acceptance for review of our BLA for Ruconest. Product sales in the nine months of 2013 amounted to €0.6 million, of which €0.4 million came in during the third quarter (€0.8 million 9M 2012). Costs of revenues amounted to € 0.4 million in the first nine months of 2013 compared to €0.8 million in the same period of 2012. In the first nine months of 2012, there was an inventory impairment of €2.3 million, while there were no impairments in 2013.

Total operating costs in the first nine months of 2013 decreased to €9.3 million from €17.9 million in the same period in 2012. Research and development costs decreased by €6.7 million to €7.4 million in the first nine months of 2013 from €14.1 million in the same period of 2012, which reflects reduced human capital costs following the restructuring in 2012, as well as lower costs related to clinical study 1310 and other cost savings. General and administrative costs decreased by €0.7 million to €1.6 million in the first nine months of 2013 compared to the first nine months of 2012, mainly as a result of the restructuring in 2012. In the first nine months of 2013, there were no impairment charges while these amounted to €1.2 million in the same period of 2012.

On 16 January 2013, the Company entered into a 8.5% convertible bond transaction of €16.35 million convertible bonds plus 16,349,999 warrants that was approved at the EGM of 28 February 2013. The bonds were repayable in cash and/or in shares in seven installments until 1 October 2013. In the first nine months of 2013, five installments were repaid in shares and one installment in cash. The seventh installment has been redeemed in cash subsequent to the reporting period, on 1 October 2013. With regards to these pay-backs in shares, the Company issued a total of 127,369,529 shares in the first nine months of 2013. Financial income in the first nine months of 2013 amounts to €0.6 million compared to €1.7 million in the same period of 2012. Financial income is non-cash in both periods and is exclusively related to decreases in the fair value of derivative financial liabilities.

As a result of the above items, net loss for the first nine months of 2013 decreased to €11.1 million from €24.2 million in the same period of 2012.

FINANCIAL POSITION

Total cash and cash equivalents (including restricted cash) increased to €13.5 million at 30 September 2013 from €6.3 million at year end 2012. The increase follows from net cash outflows from operations of €7.1 million with net cash inflows from financing activities amounting to €14.2 million and net cash inflows from investing activities amounting to €0.2 million. Financing cash flows mainly result from the 2013 issue of convertible bonds which raised gross €16.0 million in cash.

NEGATIVE EQUITY

The Company has negative equity since December 2011. The negative equity position at 30 September 2013 amounts to €1.6 million, a decrease of €6.2 million compared to 31 December 2012. The decrease is a result of new equity issues related to the 2013 convertible bonds in the first nine months of 2013, partially offset by the net loss for the period.

The negative equity position has in itself no immediate impact on the execution of Pharming's business plan, nor does it imply that the Company is legally required to issue new share capital. However, the Company is considering various options in order to reduce the negative equity and return to a positive equity position.

About RUCONEST® and Hereditary Angioedema

RUCONEST (INN conestat alfa) is a recombinant version of the human protein C1 esterase inhibitor, and is produced with Pharming's proprietary transgenic technology. RUCONEST is approved in Europe for the treatment of acute angioedema attacks in patients with HAE, a genetic disorder in which the patient is deficient in or lacks a functional plasma protein C1 esterase inhibitor, resulting in unpredictable and debilitating episodes of intense swelling. The swelling may occur in one or more anatomical areas, including the extremities, face, trunk, genitals, abdomen and upper airway. The frequency and severity of HAE attacks vary and are most serious when they involve laryngeal edema, which can close the upper airway and cause death by asphyxiation. According to the U.S. Hereditary Angioedema Association, epidemiological estimates for HAE range from one in 10,000 to one in 50,000 individuals. RUCONEST is an investigational drug in the U.S. and has been granted orphan drug designation by the FDA both for the treatment of acute attacks of HAE and for prophylactic treatment of HAE.

About Pharming Group NV

Pharming Group NV is developing innovative products for the treatment of unmet medical needs. RUCONEST® (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of angioedema attacks in patients with HAE in all 27 EU countries plus Norway, Iceland and Liechtenstein, and is distributed in the EU by Swedish Orphan Biovitrum. RUCONEST® is partnered with Santarus, Inc. (NASDAQ: SNTS) in North America and a Biologics License Application (BLA) for RUCONEST® is under review by the U.S. Food and Drug Administration. The product is also being evaluated for various follow-on indications. Pharming has a unique GMP compliant, validated platform for the production of recombinant human proteins that has proven capable of producing industrial volumes of high quality recombinant human protein in a more economical way compared to current cell based technologies. In July 2013, the Platform was partnered with Shanghai Institute for Pharmaceutical Industry (SIPI), a Sinopharm Company, for joint global development of new products. Pre-clinical development and manufacturing will take place at SIPI and are funded by SIPI. Pharming and SIPI initially plan to utilise this platform for the development of rhFVIII for the treatment of Haemophilia A. Additional information is available on the Pharming website, www.pharming.com.

This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements.

Contact

Sijmen de Vries, CEO: T: +31 71 524 7400

FTI Consulting

Julia Phillips/ John Dineen, T: +44 (0)207 269 7193

**PHARMING GROUP N.V.
CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
FOR THE QUARTER ENDED 30 SEPTEMBER 2013**

Consolidated Statement of Financial Position

Consolidated Statement of Income

Consolidated Statement of Comprehensive Income

Consolidated Statement of Cash Flows

Consolidated Statement of Changes in Equity

Notes to the Condensed Consolidated Interim Financial Statements

CONSOLIDATED STATEMENT OF FINANCIAL POSITION At 30 September 2013 (amounts in €'000)

	Note	30 September 2013	31 December 2012
Intangible assets		437	535
Property, plant and equipment	5	6,600	7,128
Restricted cash	8	<u>176</u>	<u>732</u>
Non-current assets		7,213	8,395
Inventories	6	2,737	2,101
Assets held for sale		-	242
Trade and other receivables	7	449	524
Restricted cash	8	618	309
Cash and cash equivalents	8	<u>12,701</u>	<u>5,273</u>
Current assets		16,505	8,449
Total assets		23,718	16,844
Share capital	9	2,299	10,092
Share premium		245,885	231,866
Other reserves		14,368	14,144
Accumulated deficit		<u>(264,145)</u>	<u>(263,754)</u>
Total equity		(1,593)	(7,652)
Deferred license fees income		12,772	13,495
Finance lease liabilities		1,893	1,961
Other liabilities		<u>51</u>	<u>72</u>
Non-current liabilities		14,716	15,528
Deferred license fees income		2,200	1,936
Derivative financial liabilities	10	1,928	1,215
Convertible bonds	11	2,350	-
Restructuring provision	12	2	1,232
Trade and other payables	13	3,531	3,690
Finance lease liabilities		<u>584</u>	<u>895</u>
Current liabilities		10,595	8,968
Total equity and liabilities		23,718	16,844

Notes on pages 11-18 are an integral part of these condensed consolidated interim financial statements.

CONSOLIDATED STATEMENT OF INCOME

For the nine months ended 30 September 2013 (amounts in €'000, except per share data)

	Note	30 September 2013	30 September 2012
Continuing operations:			
License fees		5,353	1,452
Product sales		614	798
Revenues		5,967	2,250
Costs of revenues		(419)	(837)
Inventory impairments		-	(2,374)
Gross profit		5,548	(961)
Income from grants		79	145
Other income		79	145
Research and development		(7,436)	(14,084)
General and administrative		(1,647)	(2,323)
Impairment charges		-	(1,222)
Share-based compensation		(225)	(266)
Costs		(9,308)	(17,895)
Loss from operating activities	14	(3,681)	(18,711)
Financial income	15	588	1,752
Financial expenses	16	(8,002)	(7,222)
Financial income and expenses		(7,414)	(5,470)
Net loss from continuing operations		(11,095)	(24,181)
Net profit from discontinued operations		-	-
Net loss		(11,095)	(24,181)
Attributable to:			
Net loss from continuing operations		(11,095)	(24,181)
Net profit from discontinued operations		-	-
Owners of the parent		(11,095)	(24,181)
Net loss from continuing operations		-	-
Net profit/(loss) from discontinued operations		-	-
Non-controlling interest		-	-
Share information:			
Basic and diluted net loss per share (€)		(0.06)	(0.38)
Weighted average shares outstanding		175,368,600	63,733,919

Notes on pages 11-18 are an integral part of these condensed consolidated interim financial statements.

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

For the nine months ended 30 September 2013 (amounts in €'000)

	30 September 2013	30 September 2012
Net loss	(11,095)	(24,181)
Foreign currency translation	0	65
Other comprehensive income, net of tax	0	65
Total recognized income and expense	(11,095)	(24,116)
Attributable to:		
Equity owners of the parent	(11,095)	(24,116)
Non-controlling interest	-	-

Notes on pages 11-18 are an integral part of these condensed consolidated interim financial statements.

CONSOLIDATED STATEMENT OF CASH FLOWS

For the nine months ended 30 September 2013 (amounts in €'000)

	Note	30 September 2013	30 September 2012
Receipts from license partners		4,804	1,217
Receipts of Value Added Tax		572	813
Interest received		6	18
Receipts of grants		79	72
Other receipts		769	556
Payments of third party fees and expenses, including Value Added Tax		(9,055)	(9,546)
Net compensation paid to board members and employees		(1,460)	(2,529)
Payments of pension premiums, payroll taxes and social securities, net of grants settled		(1,585)	(2,219)
Restructuring payments	12	(1,245)	(31)
Net cash flows used in operating activities	8	(7,115)	(11,649)
Proceeds from sale of assets		262	722
Purchase of property, plant and equipment		(21)	(613)
Net cash flows provided by/(used in) investing activities	8	241	109
Proceeds of equity and warrants issued	11	-	2,258
Proceeds of convertible bonds issued	13	16,023	8,000
Payments of transaction fees and expenses		(1,368)	(623)
Payments of finance lease liabilities		(478)	(568)
Net cash flows from financing activities	8	14,177	9,067
Increase cash		7,303	(2,473)
Exchange rate effects on cash		(123)	(20)
Cash at 1 January	8	6,314	5,065
Cash at 30 September		13,494	2,572
Cash composition:			
Restricted cash (non-current)		176	794
Restricted cash (current)		618	309
Cash and cash equivalents		12,700	1,469
Cash at 30 September		13,494	2,572

Notes on pages 11 - 18 are an integral part of these condensed consolidated interim financial statements.

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the nine months ended 30 September 2013 (amounts in €'000)

	Notes	Number of shares	Share capital	Share premium	Other reserves	Accumulated deficit	Shareholders' equity	Non-controlling interest	Total equity
Balance at 1 January 2012		51,011,647	20,405	224,495	12,325	(258,413)	(1,188)	-	(1,188)
Total recognized income and expense		-	-	-	65	(24,181)	(24,116)	-	(24,116)
Recycling equity translation reserve		-	-	-	1,384	-	1,384	-	1,384
Share-based compensation		-	-	-	266	-	266	-	266
Bonuses settled in shares	9	395,021	158	117	-	-	275	-	275
Repayments of Bonds 2012	9	21,018,200	5,432	4,492	-	-	9,924	-	9,924
Shares/warrants issued in exchange of cash		16,430,445	1,643	702	-	-	2,345	-	2,345
Adjustment nominal value per share		-	(18,752)	-	-	18,752	-	-	-
Balance at 30 September 2012		88,855,313	8,886	229,806	14,040	(263,842)	(11,110)	-	(11,110)
Balance at 1 January 2013		100,918,910	10,092	231,866	14,144	(263,754)	(7,652)	-	(7,652)
Total recognized income and expense		-	-	-	-	(11,095)	(11,095)	-	(11,095)
Share-based compensation		-	-	-	224	-	224	-	224
Bonuses settled in shares		1,281,777	13	176	-	-	189	-	189
Repayments of Bonds 2013	9, 11	127,369,529	2,896	13,824	-	-	16,720	-	16,720
Warrants exercised		300,000	3	19	-	-	22	-	22
Adjustment nominal value per share	9	-	(10,704)	-	-	10,704	-	-	-
Balance at 30 September 2013		229,870,216	2,299	245,885	14,368	(264,145)	(1,593)	-	(1,593)

Notes on pages 11-18 are an integral part of these condensed consolidated interim financial statements.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS For the nine months ended 30 September 2013

1. Company information

Pharming Group N.V. ('Pharming' or 'the Company') is a limited liability public company which is listed on NYSE Euronext Amsterdam, with its headquarters and registered office located at:
Darwinweg 24
2333 CR Leiden
The Netherlands

Pharming focuses on the development, production and commercialization of human therapeutic proteins to be used as highly innovative therapies. The Company's products are aimed at treatments for genetic disorders and surgical and traumatic bleeding. Pharming's technologies include novel transgenic platforms for the production of biopharmaceuticals, as well as technology and processes for the purification and formulation of these biopharmaceuticals.

2. Basis of presentation

These condensed consolidated interim financial statements have been prepared in accordance with IAS 34 (Interim Financial Reporting). As permitted by IAS 34, the condensed consolidated interim financial statements do not include all of the information required for full annual financial statements and should be read in conjunction with Pharming's Annual Report 2012. In addition, the notes to these condensed consolidated interim financial statements are presented in a condensed format.

These condensed consolidated interim financial statements have not been reviewed or audited and are based on IFRS as adopted by the European Union. The Board of Management has approved these condensed consolidated interim financial statements on 6 November 2013.

Going Concern Assessment

The Board of Management of Pharming has, upon preparing and finalizing these condensed consolidated interim financial statements, assessed the Company's ability to fund its operations for a period of at least one year after the date of these condensed consolidated interim financial statements.

Based on the above assessment, the Company has concluded that funding of its operations for a period of at least one year after the date of the signing of these condensed consolidated interim financial statements is realistic and achievable. In arriving at this conclusion, the following main items and assumptions have been taken into account:

- cash and cash equivalents as per the date of these financial statements;
- the €11.5 million net proceeds from the financing round announced on 9 October 2013;
- the Company's net operating cash outflows, its investments in (in)tangible assets as well as its financing payments for one year after the end of the financial statements;
- other potential sources of cash income.

These other potential sources of cash income are, including but not limited to, the following:

- under the Equity Working Capital Facility of €10.0 million, the Company has the ability, if and when needed, to utilise the remaining balance of €5.1 million until expiration of the Equity Working Capital Facility on 1 August 2014. The timing and proceeds from future tranches is subject to various parameters that are partially or entirely beyond control of the Company.
- proceeds from the exercise of warrants or options outstanding;
- capital raised by means of an additional capital markets transaction, such as non-dilutive (debt) financing, issuance of equity or a combination thereof. The timing and proceeds from such a transaction are subject to, for instance, market conditions (e.g. the share price in relation to the nominal value per share),

availability of assets to secure debt transactions as well as approvals of boards and/or shareholders (e.g. to issue additional shares); and

- receipts from existing or new license partners.

In addition, the Company may decide to cancel and/or defer certain activities in order to limit cash outflows until sufficient funding is available to resume them. Deferrals substantially relate to the timing of manufacturing-related and/or planned future clinical development activities for additional indications carried out on the initiative of Pharming.

Notwithstanding the above, the Board of Management of the Company emphasizes that the funding of the Company's operations beyond one year after these condensed consolidated interim financial statements is largely affected by its ability to generate operating cash flows from product sales and/or license fee payments from both existing and new partnerships.

As per the date of these condensed consolidated interim financial statements, with regards to its ability to generate operating cash flows from product sales and/or license fee payments, the following material uncertainties (individually or combined) have been identified which may cast significant doubt about the Company's future ability to continue as a going concern:

- receipt of a US marketing authorization by the U.S. FDA and the subsequent receipt of US\$20.0 million from our US partner Santarus (payment triggered upon the earlier of first commercial sale of Ruconest in the US or 90 days following receipt of U.S. FDA approval); and/or
- the commercial success of Ruconest in the US.

This indicates the existence of a material uncertainty which may cast significant doubt about the Company's ability to continue as a going concern.

In case the Company is ultimately not able to generate such operating cash inflows, it may ultimately enter into bankruptcy and/or sell all or a part of its assets. Such an event could have a material impact on the carrying value of, in particular, property, plant and equipment as well as inventories.

Overall, based on the outcome of this assessment, these condensed consolidated interim financial statements have been prepared on a going concern basis. Notwithstanding their belief and confidence that Pharming will be able to continue as a going concern, the Board of Management emphasizes that the actual cash flows for various reasons may ultimately (significantly) deviate from their projections. Therefore, in a negative scenario (actual cash inflows less than projected and/or actual cash outflows higher than projected) the going concern of the Company could be at risk.

3. Summary of significant accounting policies

The applied accounting principles are consistent with those as described in Pharming's Annual Report 2012.

Significant accounting estimates and judgments

The preparation of financial statements requires judgments and estimates that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities at the date of the condensed consolidated interim financial statements. The resulting accounting estimates will, by definition, seldom equal the actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities within the next financial year are addressed below.

Property, plant and equipment

At the end of the first nine months of 2013, Pharming has property, plant and equipment with a net carrying value of €6.6 million. These assets are dedicated to the production of Rhucin inventories (€5.7 million) and other corporate purposes (€0.9 million). It is assumed these asset groups will continue to be used in ongoing

production, research and development or general and administrative activities over its anticipated lifetime. The carrying value of these assets may be impaired in case of a decision to cancel and/or defer certain activities, as per the going concern assessment in Note 2.

Inventories

At the end of the first nine months of 2013, the Company has capitalized Ruconest® product and milk with an aggregate net carrying value of €2.7 million. The Company has planned for additional inventory investments after the end of the reporting period. These inventories are available for use in commercial, preclinical and clinical activities. Estimates have been made with respect to the ultimate use or sale of the product, taking into account current and expected preclinical and clinical programs for both the HAE project and other indications of Ruconest as well as anticipation of market approval(s). In doing so, best estimates have been made with respect to the timing of such events in view of both the existing and expected lifetimes of the product involved. As per the going concern assessment in Note 2, due to the early stage commercialization cycle of Ruconest the actual cash proceeds from these product sales are currently difficult to predict in terms of volumes, timing and reimbursement amounts. In addition, further inventory investments and execution of preclinical and clinical activities are subject to availability of sufficient financial resources.

Derivative financial liabilities

At 30 September 2013 the Company has presented derivative financial liabilities with a carrying value of €1.9 million. These liabilities primarily represent the fair values of warrants issued and the conversion right of the 2013 convertible bonds. These fair values are based on models using assumptions with respect to, amongst others, the exercise of the warrants on or before maturity dates as well as (historical) volatility. Actual share price developments may trigger exercise of these warrants on a different moment than anticipated in the model and also cause transfer of assets to warrant holders under conditions that are (much) more or (much) less favorable than anticipated at 30 September 2013. As a result, the difference between the value of assets transferred to warrant right holders upon exercise and the carrying value at 30 September 2013 as charged to the statement of income may be material.

Share price developments may also result in the warrants expiring unexercised while the fair value of warrants unexercised may fluctuate (significantly) until expiration. Fair value changes of warrant rights unexercised between 30 September 2013 and subsequent reporting dates are charged to the statement of income.

4. Cyclicity

In view of the Company's line of business, revenues and cash income from operating activities are subject to the timing of entering into commercial activities as well as the underlying mechanisms of the deal structure (e.g. achievement of milestones). Expenses incurred for research and development activities as well as their associated cash flows highly depend on the phase of research or development. Such items may vary significantly from period to period (i.e. from quarter to quarter) due to the timing and extent of commercial activities as well as research and development activities and are partially beyond control of the Company.

5. Property, plant and equipment

The carrying value of Pharming's property, plant decreased from €7.1 million at year end 2012 to €6.6 million at 30 September 2013 due to depreciation of these assets.

6. Inventories

Pharming's inventories increased from €2.1 million at 31 December 2012 to €2.7 million at 30 September 2013.

7. Trade and other receivables

Trade and other receivables decreased to €0.4 million at 30 September 2013 from €0.5 million at 31 December 2012.

8. Restricted cash, cash and cash equivalents, cash flows

The overall net cash position for the first half year ended 30 September 2013 and 30 September 2012 is as follows:

Amounts in €'000	30 September 2013	30 September 2012
Non-current restricted cash	176	794
Current restricted cash	618	309
Cash and cash equivalents	<u>12,700</u>	<u>1,469</u>
Balance at 30 September	13,494	2,572
Balance at 1 January	<u>6,314</u>	<u>5,065</u>
Increase for the period	7,180	(2,493)

Restricted cash represent the value of banker's guarantees issued with respect to (potential) commitments towards third parties and are primarily related to finance lease liabilities and rent.

The main cash flow items for the first nine months of 2013 and 2012 can be summarized as follows:

Amounts in €'000	30 September 2013	30 September 2012
Net cash flows used in operating activities	(7,115)	(11,649)
Net cash flows provided by/(used in) investing activities	241	109
Net cash flows from financing activities	14,177	9,067
Exchange rate effects on cash	<u>(123)</u>	<u>(20)</u>
Increase for the period	7,180	(2,493)

Cash flows used in operating activities decreased by €4.5 million, which is largely explained by the receipt of 2 milestone payments as well as the reduction of operating expenses and timing of payments.

Cash flows provided by investing activities of €0.3 million in the first nine months of 2013 concern sale of an intangible asset, while the cash used in investing activities in the same period of 2012 related to payment of manufacturing equipment acquired in 2011.

Cash flows from financing activities of €14.2 million in the first nine months of 2013 largely stems from the €16.0 million received in relation to the issue of the 2013 convertible bonds, while financing payments totalling €1.8 million related to transaction fees and expenses and payment of finance leasing terms. In the first nine months of 2012 the €9.1 million cash flows from financing activities follow receipt of €8.0 million in relation to the issue of the 2012 convertible bonds and €2.3 million from shares issued under the equity working capital facility, net of payment of transaction fees and expenses (€0.6 million) and payment of finance leases (€0.6 million).

9. Equity

Main developments total equity in the first nine months of 2013

On 28 February 2013, the EGM approved a 10:1 reverse split of the Company's stock and a subsequent reduction of the nominal share value from €0.10 to €0.01. This led to a reduction of share capital of €10.7 million which was offset against accumulated deficit. Therefore, the overall effect of this on shareholders' equity is nil.

All numbers of shares mentioned in these interim financial statements have been adjusted retro-actively for the reverse split where applicable.

Under the 2013 convertible loan agreement which is described in more detail in Note 11, Pharming issued a total number of 127,369,529 shares to 2013 bond holders.

The Company also transferred an aggregate number of 1,281,777 shares to members of the Board of Management and employees in lieu of bonus rights for the year 2012.

Main developments total equity in the first nine months of 2012

Pharming in the first nine months of 2012 issued a total of 21,018,200 shares with an aggregate fair value of €9.9 million to holders of Bonds 2012.

On 1 August 2012 the Company announced it had secured an equity working capital facility with institutional investors of up to €10.0 million for a two year term. Pharming has the option to draw from the working capital facility in tranches in exchange for ordinary shares in the capital of the Company. Pharming will retain control of the timing and amount of any funds drawn down. Pharming must give notice to the investors (a "Draw Down Notice") prior to drawing down funds. Each Draw Down Notice will state the number of ordinary shares Pharming wishes to sell to the investors ("the Draw Down Amount"). The investors have the option to purchase up to 600% of the Draw Down Amount during a 15 trading days pricing period; the total amount of cash paid for such shares to Pharming will depend on the total number of shares called by the investors and the development of the Volume Weighted Average Price (VWAP) of the shares going forward during this 15 trading days pricing period; the investors subsequently withhold a 12.5% discount on the applicable price. In the third quarter of 2012 the Company has drawn two tranches which resulted in the issue of 16,430,445 shares in total and the receipt of €2.3 million in cash. The total fair value of the shares issued amounted to €3.0 million with the €0.7 million difference to cash received of €2.3 million charged as a financial expense for €0.3 million (the difference between the fair value of the shares issued and the applicable VWAP) and to equity for €0.4 million (the 12.5% discount). On signing of the equity working capital facility the investors received warrants to purchase up to an aggregate of 1,650,000 ordinary shares in the capital of the Company. When draw downs of individual investors have exceeded a total of 25%, 50% and 75% of their commitment, additional warrants are issued. As per 30 September 2012 an additional 1,100,550 warrants have been issued. Total warrants issued in relation to the equity working capital facility in the third quarter of 2012 are 2,750,550 with an initial fair value of €297,000, recognized as a derivative financial liability.

The Company also transferred an aggregate number of 395,021 shares to members of the Board of Management and employees in lieu of bonus rights for the year 2011.

At the Annual General Meeting of Shareholders held on 14 May 2012, it was decided to reduce the nominal value per share from €0.04 to €0.01 as a result of which the Company's share capital decreased with €18.8 million and the accumulated deficit increased with same amount.

10. Derivative financial liabilities

Derivative financial liabilities recognized in the first nine months of 2013 related to 16,349,999 warrants issued in relation to the 2013 Bonds (Note 11) and conversion rights on the 2013 Bonds with the initial fair value of these items upon recognition amounting to €1,161,000 and €223,000 or €1,384,000 in total. In addition, all outstanding warrants were revalued for accounting purposes at 30 September 2013.

Movement of derivative financial liabilities for the first nine months of 2013 and 2012 can be summarized as follows:

Amounts in €'000	2013	2012
Carrying value at 1 January	1,215	1,171
Initial recognition upon issue	1,384	1,445
Fair value gains derivatives	(671)	(1,752)
Carrying value at 30 September	1,928	864

Fair value gains have been presented within financial income.

11. Convertible bonds

2013 Convertible bond

On 16 January 2013, the Company announced it had entered into a €16.35 million private convertible bonds transaction ('2013 Bonds') carrying 8.5% annual interest. In connection with this convertible bond transaction, the Company issued 16.35 million warrants with an exercise price of €0.03. The net proceeds of the 2013 convertible bonds issue amounted to €15.1 million, after deduction of a 2% discount and transaction costs of €950,000. This transaction included an advance payment of 18 million shares valued at €4,860,000. The convertible bond is repayable in 7 installments until 1 October 2013. The 2013 convertible bond transaction was approved at the EGM of 28 February 2013.

For accounting purposes, the convertible bond portion is recognized at the aggregate value of the value received minus the fair value of the derivative financial liabilities and the portion of transaction fees and expenses allocated to the convertible bond. Pre(payments) of the monthly installment plus interest can take place either in cash or in shares. Until 30 September 2013, five tranches were repaid in shares and one in cash while it was announced that the remaining seventh tranche would be repaid in cash on 1 October 2013. Based on the conditions of the convertible loan agreement, this has resulted in transfer of shares for a value higher than if such a repayment had taken place in cash only. Accordingly, a transaction loss of €4.6 million was incurred in the first nine months of 2013.

Movement of the 2013 Bonds in the first nine months of 2013 can be summarized as follows:

Amounts in €'000

Received in cash	16,023
Fair value of warrants issued	(1,161)
Fair value of conversion right	(223)
Transaction fees and expenses	<u>(868)</u>
Carrying value initial recognition	13,771
Effective interest	3,173
Fair value of shares issued for installment in the first nine months of 2013	(16,757)
Repayment in cash	(2,392)
Result bond settlements	<u>4,555</u>
Carrying value 30 September	2,350

Effective interest and the result on bonds settlements of €7.7 million in total have been charged to financial expenses (Note 16).

12. Restructuring provision

In the course of 2012, Pharming announced the closure of the US cattle facilities and a restructuring of its Dutch operations. A restructuring provision was created for the costs related to the severance payments and other employee-related costs. These amounts have been paid during the first half of 2013.

13. Trade and other payables

Trade and other payables balances decreased from €3.7 million at year end 2012 to €3.5 million at 30 September 2013 mainly as a result of a decrease of the accounts payables.

14. Loss from operating activities

In the first nine months of 2013, the Company reported a loss from operating activities of €3.7 million compared to €18.7 million in the same period of 2012. The €15.0 million decrease is mainly a result of increased revenues through milestones from Santarus (US\$5.0 million) and SIPI (€1.1 million), lower human capital costs (€3.5 million) following the reduction of the number of employees, mostly through the restructuring in 2012, and lower costs associated with Study 1310 (€2.5 million) as well as other cost-savings (€0.5 million).

As explained in Note 4, Pharming operates in an industry in which revenues and expense are to some extent varying based on the timing of events such as entering into commercial agreements, achievement of milestones or the phase of research or development. These activities are partially beyond control of the Company.

15. Financial income

Financial income in the first nine months of 2013 and 2012 amounted to €0.6 million and €1.7 million, respectively, which mainly related to the decreases in the fair value of derivative financial liabilities (Note 10).

16. Financial expenses

Financial expenses of €8.0 million in the first nine months of 2013 were mainly related the 2013 Bonds and to other items such as foreign currency results and interest on finance leases. The financial expenses of €7.2 million in the same period of 2012 are mainly associated with 2012 Bonds.

17. Operating segments

The Company is active in one operating segment which is the recombinant proteins business segment.

18. Commitments and contingencies

In the first nine months of 2013 there were no material changes to the commitments and contingent liabilities from those disclosed in Note 31 of the 2012 Annual Report.

19. Events after the end of the reporting period

On 1 October 2013, the Company repaid the seventh tranche of the 2013 convertible bond, amounting to €2.4 million, in cash.

On 9 October 2013, the Company announced a €12.0 million private placement with institutional investors.

The total number of outstanding shares at 7 November 2013 amounts to 332,434,319.

The authorized number of shares of the Company is 450 million with fully diluted shares as per 7 November 2013 summarized as follows (in millions):

Shares	332.4
Warrants	49.5
Options	4.8
Long Term Incentive Plan	<u>1.3</u>
Total	388.0